Mitral valve repair is the standard of care for degenerative mitral valve pathology, as established by the median sternotomy approach. Equivalently excellent results can be achieved by a variety of more minimally invasive approaches depending on institutional experience and preferences. At the Minneapolis Heart Institutet, we have experience with and utilize all approaches to mitral valve repair for degenerative disease including full and hemisternotomy, right thoracotomy, mini-thoracotomy and heart port approaches. We believe that logistic, economic, and anticipated benefit constraints currently limit the application and the robotic technology. Leaflet maneuvers continue to be important in mitral valve repair, but recently we have revisited the concept of simplifying a ''complex'' repair in the setting of a subset of severe degenerative (Barlow's) disease by utilizing only an oversized mitral valve ring with excellent results. As suggested by others, in the appropriate setting of bileaflet prolapse resulting in central symmetric regurgitation, a simplified approach may be just as effective as longer, more complicated operations. 1. Degenerative MV disease can be repaired in the majority of cases with a durable long-term result and very low reoperative rate. Experienced centers can reproducibly expect repair rates of over 90% with a 1% failure rate/year. 2. The life expectancy curves for those that undergo repair approach those of the normal life expectancy curves for men and women, and in certain cases may be better than twins without the disease. 3. The repair techniques include a finite list of leaflet maneuvers and should always include the placement of a ring for annular fixation. The leaflet maneuvers include various resections, plications, commissure, and cleft closures; edge-toedge repairs; and artificial chord placement based upon the findings of the echo and the appearance of the degenerative pathology at the time of surgery.
KEY WORDSGiven the evolution and success of these surgical tenets, the American College of Cardiology/American Heart Association guidelines have recommended MV surgery for symptomatic MR and minimally symptomatic MR in the presence of left ventricular dilation or dysfunction, and-at centers of excellence-can be considered for asymptomatic patients. Secondary to these recommendations, an estimated 40,000 MV operations take place in the US per year; given the low prevalence of rheumatic disease in the US, the majority of these patients are sent to surgery with MR and the majority of them are potential candidates for MV repair rather than replacement.